⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
OTLK News
Outlook Therapeutics, Inc. Common Stock
Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
globenewswire.com
OTLK
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
globenewswire.com
OTLK
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
globenewswire.com
OTLK
Form 8-K
sec.gov
OTLK
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
globenewswire.com
OTLK
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
globenewswire.com
OTLK
2026 Back of the Eye Disorders Market Research Report (2nd Edition): A Development Pipeline Consisting of ~690 Approved or Clinical-Stage Therapeutic Candidates
globenewswire.com
KODK
OTLK
ALDX
OCUL
REGN
ABBV
NVS
BHC
SUN
Form 8-K
sec.gov
OTLK
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
globenewswire.com
OTLK